Search

Your search keyword '"Avisar, Noa"' showing total 22 results
Start Over Author "Avisar, Noa"
22 results on '"Avisar, Noa"'

1. Real-Time Artificial Intelligence–Based Guidance of Echocardiographic Imaging by Novices: Image Quality and Suitability for Diagnostic Interpretation and Quantitative Analysis

Author

Mor-Avi, Victor, Khandheria, Bijoy, Klempfner, Robert, Cotella, Juan I., Moreno, Merav, Ignatowski, Denise, Guile, Brittney, Hayes, Hailee J., Hipke, Kyle, Kaminski, Abigail, Spiegelstein, Dan, Avisar, Noa, Kezurer, Itay, Mazursky, Asaf, Handel, Ran, Peleg, Yotam, Avraham, Shir, Ludomirsky, Achiau, and Lang, Roberto M.

Published
2023
Full Text
View/download PDF

3. NOVEL ARTIFICIAL INTELLIGENCE GUIDANCE ALGORITHM ENABLES ACQUISITION BY NOVICES OF DIAGNOSTIC QUALITY ECHOCARDIOGRAPHIC IMAGES

Author

Klempfner, Robert V., primary, Lang, Roberto M., additional, Mor-Avi, Victor, additional, Guile, Brittney, additional, Hipke, Kyle, additional, Cotella, Juan Ignacio, additional, Kaminski, Abigail, additional, Moreno, Merav, additional, Spiegelstein, Dan, additional, Avisar, Noa, additional, Ludomirsky, Achiau, additional, Kezurer, Itay, additional, and Khandheria, Bijoy K., additional

Published
2023
Full Text
View/download PDF

9. A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects

Author

Adar,Liat, Avisar,Noa, Lammerich,Andreas, Kleiman,Robert B, Spiegelstein,Ofer, Adar,Liat, Avisar,Noa, Lammerich,Andreas, Kleiman,Robert B, and Spiegelstein,Ofer

Abstract

Liat Adar,1 Noa Avisar,1 Andreas Lammerich,2 Robert B Kleiman,3 Ofer Spiegelstein1 1R&D, Teva Pharmaceutical Industries Ltd, Netanya, Israel; 2Biosimilars Clinical Development, CPP Teva ratiopharm, Merckle GmbH, Ulm, Germany; 3Global Cardiology, eResearch Technology Inc, Philadelphia, PA, USA Abstract: Tbo-filgrastim is a recombinant human granulocyte colony-stimulating factor approved by the US Food and Drug Administration to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. We assessed the effect of tbo-filgrastim on cardiac conduction and repolarization in healthy subjects. A three-arm, parallel-group, active- and placebo-controlled, double-blind study randomized healthy adults to a single 5 µg/kg intravenous tbo-filgrastim infusion, a single intravenous placebo infusion, or a single 400 mg moxifloxacin oral dose. The primary end point was placebo-corrected time-matched change from baseline in QT interval corrected using a QT individual correction (QTcI) method. Secondary end points included heart rate, PR interval, QRS duration, change in electrocardiogram patterns, correlation between QTcI change from baseline (milliseconds) and tbo-filgrastim serum concentrations, and safety variables. A total of 145 subjects were enrolled (50 tbo-filgrastim, 50 placebo, 45 moxifloxacin). Peak placebo-corrected change from baseline for QTcI with tbo-filgrastim was 3.5 milliseconds, with a two-sided 95% upper confidence interval of 7.2 milliseconds, demonstrating no signal for any tbo-filgrastim effect on QTc. Concentration-effect modeling showed no evidence of an effect of tbo-filgrastim on cardiac repolarization. Tbo-filgrastim produced no clinically significant changes in other electrocardiogram parameters. Tbo-filgrastim was well tolerated. Keywords: tbo-filgrastim, electrocardiogram, QT interval

Published
2015

17. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.

Author

Gladkov, Oleg, Moiseyenko, Vladimir, Bondarenko, Igor N., Shparyk, Yaroslav, Barash, Steve, Adar, Liat, and Avisar, Noa

Subjects
BREAST tumors, CANCER chemotherapy, CONFIDENCE intervals, DOXORUBICIN, FILGRASTIM, MEDICAL cooperation, NEUTROPENIA, RESEARCH, DOCETAXEL, RANDOMIZED controlled trials, TREATMENT effectiveness, DATA analysis software, DESCRIPTIVE statistics
Abstract

Objectives. This study aimed to evaluate the efficacy and safety of once-per-cycle balugrastim versus pegfilgrastim for neutro-phil support in breast cancer patients receiving myelosuppressive chemotherapy. Methods. Breast cancer patients (n =256) were randomized to 40 or 50 mg of subcutaneous balugrastim or 6 mg of pegfilgrastim ≈24 hours after chemotherapy (60 mg/m² doxorubicin and 75 mg/m² docetaxel, every 21 days for up to 4 cycles).The primary efficacy parameter was the duration of severe neutropenia (DSN) in cycle 1. Secondary parameters included DSN (cycles 2-4), absolute neutrophil count (ANC) nadir, febrile neutropenia rates, and time to ANC recovery (cycles 1-4). Safety, pharmacokinetics, and immunogenicity were assessed. Results. Mean cycle 1 DSN was 1.0 day with 40 mg of balugrastim, 1.3 with 50 mg of balugrastim, and 1.2 with pegfilgrastim (upper limit of 95% confidence intervals for between-group DSN differences was <1.0 day for both balugrastim doses versus pegfilgrastim). Between-group efficacy parameters were comparable except for time to ANC recovery in cycle 1 (40 mg of balugrastim, 2.0 days; 50 mg of balugrastim, 2.1; pegfilgrastim, 2.6). Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim. Antibody response to balugrastim was low and transient, with no neutralizing effect. Conclusion. Once-per-cycle balugrastim is not inferior to pegfilgrastim in reducing cycle 1 DSN in breast cancer patients receiving chemotherapy; both drugs have comparable safety profiles. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

18. PREDICT modeling and in-silico screening for G-protein coupled receptors

Author

Shacham, Sharon, primary, Marantz, Yael, additional, Bar-Haim, Shay, additional, Kalid, Ori, additional, Warshaviak, Dora, additional, Avisar, Noa, additional, Inbal, Boaz, additional, Heifetz, Alexander, additional, Fichman, Merav, additional, Topf, Maya, additional, Naor, Zvi, additional, Noiman, Silvia, additional, and Becker, Oren M., additional

Published
2004
Full Text
View/download PDF

20. Modeling the 3D structure of GPCRs from sequence

Author

Shacham, Sharon, primary, Topf, Maya, additional, Avisar, Noa, additional, Glaser, Fabian, additional, Marantz, Yael, additional, Bar-Haim, Shay, additional, Noiman, Silvia, additional, Naor, Zvi, additional, and Becker, Oren M., additional

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results